Assertio Holdings 2025 Q3 Earnings Net Income Surges 491.8% as Profitability Returns

Assertio Holdings (ASRT) delivered a stunning turnaround in Q3 2025, reporting $49.46 million in revenue and $0.12 EPS, far exceeding expectations. The company narrowed full-year guidance to $110M–$112M in product sales and $14M–$16M in adjusted EBITDA, reflecting Rolvedon’s pull-forward and Indocin headwinds.

Revenue

Total product sales, net, reached $49.46 million in Q3 2025, a 69.4% increase from $29.20 million in Q3 2024. ROLVEDON led with $38.57 million in net sales, driven by distributor orders to secure supply during label integration. INDOCIN products contributed $4.85 million, while Sympazan and SPRIX generated $2.83 million and $1.69 million, respectively. Other products added $1.53 million to the total.

Earnings/Net Income

Assertio returned to profitability with EPS of $0.12, reversing a $0.03 loss in Q3 2024 (500% positive change). Net income surged to $11.45 million, a 491.8% increase from a $2.92 million loss. This remarkable turnaround underscores improved operational efficiency and cost management.

Price Action

The stock price rose 4.46% in the latest trading day and 7.52% for the week, though it declined 8.45% month-to-date.

Post-Earnings Price Action Review

The strategy of buying ASRT shares on revenue announcement dates and holding for 30 days yielded cumulative returns of 17.5% over three years, with an average annual return of 5.8%. This outperformance, despite market volatility, highlights the effectiveness of capitalizing on Assertio’s revenue growth momentum.

CEO Commentary

CEO Mark Reisenauer emphasized Rolvedon’s $38.6M sales, driven by a two-quarter pull-forward to ensure patient access during label integration. He noted Sympazan’s growth and challenges from Indocin generic competition but expressed optimism about leveraging Assertio’s oncology expertise and strong balance sheet to drive long-term value.

Guidance

Assertio narrowed 2025 guidance to $110M–$112M in product sales and $14M–$16M in adjusted EBITDA. Rolvedon sales are expected to resume post-Q1 2026, while temporary cash flow declines in Q4 2025 and Q1 2026 are anticipated due to the pull-forward.

Additional News

1. C-Level Promotion: Paul Schwichtenberg was promoted to President and COO, signaling a strategic focus on operational streamlining.

2. Director Sale: Director Stark filed to sell 8,959 shares of restricted stock via a prearranged trading plan.

3. Supply Agreement: Assertio executed a long-term supply agreement with Omni for Rolvedon, ensuring stable pricing and supply.

Assertio’s Q3 performance reflects a strategic pivot toward core growth assets and operational efficiency, with a strong cash balance of $93.4M as of September 30, 2025. Investors await Rolvedon’s post-integration recovery and Sympazan’s market awareness campaigns to sustain momentum.